Industry News: Real-World Evidence from Mobile Devices, the Opioid Crisis, and New Data from Teva Pharmaceuticals

Keeping up with what’s going on in the industry can be a bit of a headache; there are new studies coming out every day and new initiatives launching all the time. Don’t stress, we’ve neatly chunked together 3 of the most interesting and useful stories from the last month – so you don’t have to![…]

Interested in joining our Clinical Team?

Overview Ignite Data currently have a position available within the rapidly-growing clinical team for an enthusiastic and pro-active biomedical science (or similar) graduate. This role will be a fantastic opportunity to develop your skills and experience by working alongside well-known figures from the clinical research and healthcare worlds. The confluence of clinical research and healthcare[…]

‘The Clinical Trials System is Broken’

Earlier this month, Janet Woodcock, Director of the Center for Drug Evaluation and Research at the US Food and Drug Administration (pictured below), said that the clinical trials system in the US is ‘broken’. In her words: “I personally believe, like many other people, that the clinical trial system we have right now is broken.[…]

The UK Government Should Act Urgently to Ensure NHS Data Security

An independent review of the UK life sciences industry has advised that the government must act urgently to ensure that patients and UK taxpayers gain from new commercial applications of NHS data. The good news: NHS data has huge potential Sir John Bell, a Professor of Medicine at Oxford University, led the government-commissioned review. He[…]

Kymriah: ‘Living Drug’ Approved to Treat Childhood Leukaemia

Signalling a new era in cancer care, this week the US Food and Drug Administration approved the first treatment that genetically engineers patients’ own blood cells to fight childhood leukaemia. Kymriah is the first gene therapy to be approved for use in humans in the United States – an historic step forward. The drug, Kymriah,[…]

Industry News: Treating Cancer on the NHS, Healthcare Interoperability, and Are Clinical Trial Patients Different?

Keeping up with what’s going on in the industry can be a bit of a headache; there are new studies coming out every day and new initiatives launching all the time. Don’t stress, we’ve neatly chunked together 3 of the most interesting and useful stories from the last month – so you don’t have to![…]

New ‘Eyeprint’ Technology to Prevent Medical Record Mix-Ups

A medical centre in California, USA is changing the way it identifies patients as they come in the door. The Community Regional Medical Center in Fresno is rolling out a new initiative that will use the eyeprint of registered patients to reduce identification errors. This advance comes after patient matching has been pushed into the[…]

Industry News: Soliris, a Shaky Cardiovascular Treatment, and How Pharma Is Changing Due to a Demand for RWE

Keeping up with what’s going on in the industry can be a bit of a headache; there are new studies coming out every day and new initiatives launching all the time. Don’t stress, we’ve neatly chunked together 3 of the most interesting and useful stories from the last month – so you don’t have to![…]

Ignite Data Named as a Game Changer in the Thames Valley for 2017

The Thames Valley is rich in established, mature tech-based businesses – that’s clear. What about the young start-ups; the unsung heroes that are working to innovate and grow here? ConnectTVT was launched in June 2014 to draw attention to the inspiring business in our area. Ignite Data is delighted to be named of ConnectTVT’s 2017[…]

How the FDA is Embracing Real-World Data

In 2016, the FDA and Flatiron Health started a collaboration to learn from Real-World clinical data. That Real-World Data (RWD) originates from the health records of cancer patients that Flatiron analyses. Flatiron collects data on what medications a patient has taken, and how they have responded to them. The goal of the collaboration is to[…]

Industry News: The Human Project, Sanofi’s Push for RWD, and a Pact to Improve Breast Cancer Outcomes

Keeping up with what’s going on in the industry can be a bit of a headache; there are new studies coming out every day and new initiatives launching all the time. Don’t stress, we’ve neatly chunked together 3 of the most interesting and useful stories from the last month – so you don’t have to![…]

Case Study: PAREXEL’s Connected Journey

The biopharmaceutical industry is changing rapidly. In recent years there has been a definite push to embrace the potential of Real-World Data (RWD) to support clinical trial findings. Gone are the days when data collected during efficacy trials was enough to convince payers or national agencies of a drug candidate’s value. The pressure to adapt[…]

Cardiac Patients in Trials Don’t Reflect Real-World Populations

Last week we asked the question ‘Does RWE influence clinical practice?’, but a recent study published by JAMA Internal Medicine has taken a different approach to the issue of RWE, clinical trials and their translation to clinical practice. Clinical trials are the foundation of evidence-based medicine – but what if the patients that take part[…]

Industry News: GSK’s Second Salford-Lung Study, Data from Novartis, and How to Approach Real-World Studies

Keeping up with news from across the industry can be a bit of a headache. There are new studies coming out every day and new initiatives launching all the time. Don’t stress. We’ve neatly chunked together 3 of the most interesting stories from the last month – so you don’t have to! This month we[…]

Data Sharing, Cyber Attacks and Digital Trust

Last week, current affairs media outlet Racontuer published a piece titled, ‘Would you share your patient data to save lives?’, this was then followed with the subtext, ‘Used ethically, NHS patient data has the potential to improve healthcare and save lives.’ On Friday the news then hit that a global cyber attack had hit 48[…]

The Cancer Drugs Fund – A Missed Opportunity for Real-World Data

Last week UK researchers broke the news that the Cancer Drugs Fund in England was a “huge waste of money”, and may have caused patients to suffer needlessly from the side effects of the drugs supplied by this fund. What is the Cancer Drugs Fund? The Cancer Drugs Fund was an addition made the the[…]

Case Study: Verily’s Project Baseline

Verily Life Sciences, formerly Google Life Sciences, is partnering with Stanford and the Duke University School of Medicine on a ground-breaking new study known as Project Baseline. What will Project Baseline do? Project Baseline will collect a comprehensive set of data from 10,000 volunteers. These participants will have their biological systems simultaneously and longitudinally measured[…]

Case Study: Patient Recruitment for a Multiple Sclerosis study with Canbex

Ignite Data are currently utilising their powerful technology-enhanced solution to identify and recruit patients onto a Canbex Therapeutics Phase II efficacy study in Multiple Sclerosis. Over a period of 3 months large GP Practices within key networks were digitally contracted to participate in this vital research, generating a potential patient pool of over 250,000 patients.[…]

Case Study: Patient Recruitment for a cardiovascular study with Synexus

Ignite Data recently completed a very successful project involving the use of a powerful technology-enhanced solution to identify and recruit patients onto a major global cardiovascular study. Ignite Data were engaged by Synexus to support and enhance their patient recruitment strategy. The first step involved Ignite Data’s Study Research Team engaging with GP Practices close[…]

Evidence

Evidence Europe conference

Ignite Data were delighted to attend the Evidence Europe conference at Victoria Park Plaza in London at the end of February. Approximately 200 attendees, representing stakeholders from market access, health economics, epidemiology and clinical research, gathered to discuss the rapidly changing landscape of drug development and reimbursement, and the unique challenges these changes will bring[…]

ConnectTVT ones to watch

Our latest Ones to Watch, in partnership with NatWest, are Ignite Data who specialise in patient recruitment, patient feasibility and eSourced data using digital patient records in the UK. We caught up with Managing Director, Dan Hydes. What was the inspiration behind Ignite Data? We wanted to build a high value business in a growth area whilst trying[…]

GSK touts real-world data for COPD drug in Salford study

A great article in BioWorld explaining the benefits of e-sourced data in clinical research. Ignite Data is working with its integrated record partner in the UK to find all kind of different benefits to patients using the technologies applied in the Salford Lung Study: Glaxosmithkline plc has reported statistically significant results in what it claims is[…]

GSK teams up with Google on bioelectronic medicines

PharmaTimes takes a look at GSK and Google’s joint effort into bioelectronic medicines: GlaxoSmithKline is teaming up with Google’s parent company Alphabet to create a new company focused on developing bioelectronic medicines. The UK drugs giant is setting up a joint venture – Galvani Bioelectronics – with Alphabet division Verily Life Sciences to enable research,[…]

Caldecott 3: Review of Data Security, Consent and Opt-Outs

‘Research is an essential part of improving the safety and quality of care: research facilitates the development of innovative new medicines, treatments and services. The National Research Ethics Service provides an ethical review of all health research involving patients in England. Researchers have worked hard to gain the trust of research participants: 2.2 million patients[…]